MindWalk Holdings (HYFT) Company Report

Analyst Coverage

Research analysts covering MindWalk Holdings.

Recent press releases and 8-K filings for HYFT.

MindWalk Holdings Corp. Appoints New CFO and Announces AGM Results

HYFT

CFO Change

Board Change

Auditor Change

MindWalk Holdings Corp. announced the appointment of R. Scott Areglado as Chief Financial Officer, effective October 20, 2025.
Mr. Areglado brings over 25 years of financial leadership experience from the healthcare, life sciences, and technology sectors, having previously served as CFO for BrainsWay Ltd. and iCAD, Inc..
At its 2025 Annual General Meeting of Shareholders on October 9, 2025, Dr. Jennifer Bath, Jon Lieber, and Dirk Witters were elected to the Board of Directors, and Davidson & Company LLP was re-appointed as auditor.
Mr. Kamil Isaev resigned from the Board, effective immediately, after his re-election bid received 68% withheld votes.

Oct 21, 2025, 1:42 PM

MindWalk Holdings Corp. Announces Share Repurchase Program

HYFT

Share Buyback

MindWalk Holdings Corp.'s Board of Directors has authorized a share repurchase program.
The company may repurchase up to 2.3 million common shares, representing approximately 5% of its currently issued and outstanding shares.
The program is set to commence on October 15, 2025, and will run for a twelve-month period, ending no later than October 15, 2026.
CEO Jennifer Bath stated that the program underscores confidence in MindWalk's future and provides flexibility to repurchase shares when the market price is believed to be disconnected from its intrinsic value.

Oct 9, 2025, 1:36 PM

MindWalk Holdings Corp. Advances AI-Designed GLP-1 Program for Longevity

HYFT

New Projects/Investments

MindWalk Holdings Corp. announced a significant advancement in its AI-designed GLP-1 therapeutics program, introducing a first-in-class dual-pathway regimen for aging and longevity.
The company's LensAI™ platform identified a novel connection between GLP-1 biology and a second, non-overlapping pathway, leading to the development of a proprietary companion therapeutic for co-administration with its GLP-1 receptor agonists.
This strategic evolution positions MindWalk to target the high-growth longevity therapeutics market, which is projected to exceed $60 billion by 2030.
MindWalk expects to provide updates on lead selection for the companion therapeutic and preclinical combination design parameters in the coming quarters.

Sep 22, 2025, 1:51 PM

MindWalk Holdings Corp. Reports Record Q1 2026 Revenue and Narrowed Losses

HYFT

Earnings

Revenue Acceleration/Inflection

M&A

MindWalk Holdings Corp. reported record revenue of $7.6 million for its first fiscal quarter of 2026, ended July 31, 2025, representing a 45% year-over-year increase.
The company's gross margin expanded to 53%, with gross profit reaching $4.0 million, and net loss improved to $3.0 million compared to $4.0 million in the prior year.
MindWalk strengthened its balance sheet with a cash balance of $5.0 million at quarter-end, supplemented by $16.1 million in net proceeds from the divestiture of its Netherlands operations.
The company completed its rebranding and advanced its dengue vaccine program into preclinical manufacturing, further validating its LensAI platform.

Sep 15, 2025, 12:51 PM

MindWalk Holdings Corp. Reports Q1 2026 Results and Completes Divestiture

HYFT

Earnings

M&A

Profit Warning

MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) reported revenue of $3.2 million for the three months ended July 31, 2025, marking a 27.8% increase compared to the same period in 2024, alongside a net loss from continuing operations of $4.1 million.
The company completed the divestiture of its IPA Europe B.V. on August 6, 2025, for $12 million USD, generating $11.7 million USD in net proceeds.
As of July 31, 2025, MindWalk had $5.0 million in cash on hand and stated that this amount is insufficient to fund operations for at least one year, raising material uncertainties regarding its ability to continue as a going concern without securing additional financing.
Management identified a material weakness in internal controls over financial reporting as of July 31, 2025, attributed to insufficient resources for complex technical accounting issues, with remediation efforts ongoing.